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ABSTRACT 
 
Background:  Streptococcus pneumoniae is the most common bacterial cause of acute otitis 
media (AOM).  A few randomized controlled trials (RCTs) have found that administration of the 
pneumococcal conjugate vaccine (PCV) to infants is effective at decreasing episodes of AOM 
during infancy and early childhood.  However, these RCTs were in high-income countries in 
populations with a relatively low burden of suffering due to otitis media.  This trial is the first to 
use data from a randomized trial to investigate the effectiveness of a PCV at decreasing otitis 
media in a country with a high level of morbidity and mortality due to otitis media. 
 
Methods:  The effects of the 7-valent PCV and Haemophilus influenzae type b (Hib) conjugate 
vaccine on AOM with TM perforation were compared through a secondary analysis of data that 
were collected during a blinded, randomized trial in Bangladesh in 2004 and 2005.  Infants 
received vaccines at 6, 10, and 14 weeks of age and their caregivers were interviewed weekly 
from 6˗24 weeks of age.  Caregiver report of ear drainage was considered to represent AOM 
with TM perforation.  Weekly interviews also asked about antibiotic use and other illness 
symptoms. 
 
Results:  340 infants were enrolled and randomized.  Data were collected and analyzed for 328 
infants.  Baseline data were comparable between the two groups.  In the PCV and Hib vaccine 
groups there were similar numbers of episodes of AOM with TM perforation and similar 
numbers of infants who had one or more episodes.  However, in the PCV group there were fewer 
positive weekly reports of AOM with TM perforation total.  Infants in the PCV group had an 
average of 1.2 weekly reports per episode, compared to those in the Hib vaccine group who had 
an average of 2.6 weekly reports per episode (p = 0.005).  In the PCV group antibiotics were 
given during the first week of an episode of AOM with TM perforation in 82% of weeks 
compared to only 25% of such weeks in the Hib vaccine group (risk difference: 57%, 95% C.I. 
23% – 90%).  A multivariate analysis that accounted for the type of vaccine and for antibiotics 
given during the first week of an episode found that neither had a statistically significant effect 
on the number of weekly reports per episode of AOM with TM perforation (p= 0.10 for vaccine 
type, p= 0.33 for antibiotics).  
 
Conclusions:  The results suggest that the 7-valent PCV does not cause a statistically significant 
difference in the incidence or duration of episodes of AOM with TM perforation among infants 
in Bangladesh.  However, due to significant concerns about the internal validity of the study, the 
accuracy of these results is unclear and they should be interpreted with caution.  The potential for 
measurement errors, the use of the Hib vaccine in the comparison group, and the poor adherence 
to the intervention constitute the greatest concerns about the internal validity of the study.  On 
March 21, 2015, Bangladesh added a 10-valent PCV to its national immunization program, 
creating the opportunity for the use of historical cohort studies to research this topic in the future. 
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INTRODUCTION 
 
 Streptococcus pneumoniae is a bacterial pathogen that is responsible for an estimated 1 
million or 1.8% of all deaths* and 35 million or 1.4% of all disability-adjusted life-years 
(DALYs) worldwide every year.1,2  Most of the morbidity and mortality due to S. pneumoniae is 
caused by pneumonia and meningitis, but otitis media, sinusitis, and bacteremia are significant 
contributors as well.3  S. pneumoniae is responsible for more deaths in children under 5 than any 
other single pathogen.4  It causes 8% of deaths in children under 5 years of age and 11% of 
deaths in children between 1 month and 5 years of age.5   
Compared to other age groups, children under 5 are disproportionally affected by S. 
pneumoniae infections.  Despite being only 9% of the population, children under 5 account for 
an estimated 22% of the deaths, 52% of the DALYs, and 54% of the years of life lost (YLLs) 
due to S. pneumoniae.1,2,6  In addition to this age-related disparity, there are geographic and 
economic disparities in the burden of suffering due to S. pneumoniae in children under 5.  Africa 
and Southeast Asia account for an estimated 77% of the all deaths due to S. pneumoniae in 
children under 5, even though they are home to 48% of the world’s children under 5.5  From an 
economic perspective, 61% of all deaths due to S. pneumoniae in children under 5 occur in only 
ten low and middle-income countries in Africa and Asia.5  
Several strategies have been suggested for decreasing the large burden of suffering due to 
S. pneumoniae and for reducing the disproportionately high morbidity and mortality it causes 
among children under 5 in low and middle-income countries in Africa and Asia.  Suggested   
 
 
 
 
 
*There is substantial variation in estimates of deaths due to S. Pneumonia.  The estimate above is for the 
year 2010 from the Global Burden of Disease project undertaken by the Institute for Health Metrics and 
Evaluation (IHME) associated with the University of Washington.1,2  Another estimate by the IHME was 
significantly lower.4  An estimate generated by the World Health Organization (WHO), Pneumococcal 
vaccines Accelerated Development and Introduction Plan (PneumoADIP), and Global Alliance for 
Vaccines and Immunization (GAVI) was significantly higher.5  
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strategies include expanding pneumococcal conjugate vaccine (PCV) coverage, decreasing 
secondhand smoke exposure, improving nutrition, increasing breastfeeding, providing zinc 
supplementation, and boosting access to antibiotic treatment for bacterial pneumonia.7-10  This 
master’s paper investigates one of those strategies, the expansion of PCV coverage, which has 
been a significant focus of international efforts and research since 2000.3,11  
Efficacy and Impact of the PCV 
A meta-analysis from 2009 examined seven randomized, controlled trials (RCTs) (total n 
= 111,798) and calculated the effects of the 7, 9, and 11-valent PCVs in children <29 months of 
age.12  It found that the PCV was effective at reducing invasive pneumococcal disease (IPD) 
(relative risk (RR): 0.42, 95% CI 0.27 – 0.65).12  One of the RCTs  even found that the 9-valent 
PCV decreased all-cause mortality among children in Kenya (n = 17,437, RR: 0.86, 95% CI 0.77 
– 0.98).  Two of the RCTs found trends toward reductions in all-cause mortality among children 
in the Philippines with the 11-valent PCV (n = 12,191, RR: 0.88, 95% CI 0.5 – 1.5) and in South 
Africa with the 9-valent PCV (n=37,259, RR: 0.95, 95% CI 0.8 – 1.1).12  When those results 
were pooled with a smaller study of the 7-valent PCV in Finland (n= 1,251, RR: 1.50 95% CI 0.1 
– 36), the meta-analysis found that PCVs caused a relative reduction of 11% in all-cause 
mortality (n = 68,138, RR: 0.89, 95% CI 0.80 – 0.98).12   
 The use of the PCV began in high-income countries in 2000, and its effects in those 
countries have been positive and well-documented.3  A non-systematic review described nine 
historical comparison studies that compared the incidence of IPD before and after the addition of 
the 7-valent PCV to the national immunization schedules of eight high-income countries.3  The 
studies found reductions of 37% – 80% in IPD due to all S. pneumoniae serotypes and reductions 
of 79% – 100% in IPD due to the 7 vaccine serotypes.3  Despite the substantial evidence that the 
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PCV is beneficial and efficacious at reducing morbidity and mortality, it is still only available 
and accessible to 49% of the world’s children.13  
PCV Use in Lower and Middle-Income Countries 
As of 2008, the PCV was not included in the immunization schedules of any low or 
middle-income countries.3  However, PCV coverage has improved substantially in the last 7 
years.13  One of the major organizations leading the effort to increase the number of children 
who receive the PCV is the Global Alliance for Vaccines and Immunizations (GAVI).  Much of 
the expansion in PCV coverage has been through a GAVI program that offers significant 
financial and technical assistance to countries with a gross national income of less than $1,000 
per person.3,11  Of the 73 GAVI-eligible countries, 53 currently provide PCV coverage through 
their national immunization programs and 12 others are in the process of adding PCV 
coverage.13  Among the ten countries with the most childhood deaths due to S. pneumoniae, 
seven have added the PCV to their immunization programs since 2011.  In the three remaining 
countries, India, China, and Indonesia, the PCV is not a part of their immunization programs.10  
Since these three countries account for 40% of the world’s population, it is not surprising that 
51% (69 million) of infants worldwide live in countries where the PCV is not part of the national 
immunization program.13  Of these three countries, the burden of suffering due to S. pneumoniae 
is greatest in India, which has more childhood deaths due to S. pneumoniae than any other 
country.  India accounts for about 17% of the world’s total, compared to 3.6% in China and less 
than 2.3% in Indonesia.5   
Potential Relevance of the Analysis 
The analysis described in this master’s paper is relevant because it has the potential to 
provide additional evidence to support the expansion of PCV coverage, especially in India.  It is 
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a secondary analysis of data from a randomized trial, and it investigates the effect of the 7-valent 
PCV on acute otitis media (AOM) with tympanic membrane (TM) perforation among infants in 
Bangladesh.*  (See Appendix A for more about AOM with TM perforation and the other types 
of otitis media.)  Although the existing evidence for the benefit of the PCV described above is 
already substantial, this analysis could add to it in two ways.   
1) This analysis is the first to investigate the effect of the PCV in the WHO South-East 
Asia region, making it potentially the first study to demonstrate that the PCV is effective against 
the S. pneumoniae serotypes in that region.12,14  This is important because of the considerable 
geographic variation in S. pneumoniae serotypes, such that in Asia only about 50% of 
pneumococcal serotypes are covered by the 7-valent PCV, compared to 82% in North America 
and 72% in Europe.15  The Indian Academy of Pediatrics Committee on Immunization even 
expressed concerns about the implications of geographic variation of S. Pneumonia  
 
* Eliza RoyA and Mark SteinhoffB,C came up with the original idea for this secondary analysis.  I wrote a 
manuscript that carried out their original idea, with guidance and editing from Mark Steinhoff.   That 
manuscript is separate from this master’s paper.  This master’s paper is similar to that manuscript because 
it investigates the same hypothesis using the same data.  However, there are several key differences, 
which are that the master’s paper has a different introduction, uses different terminology and outcome 
variables, adjusts for confounders in the statistical analysis, and has different interpretations of the results.  
The manuscript is in the process of being prepared for publication, and its most recent version is included 
as Appendix C of this master’s paper.  The manuscript is entitled, “Clinical Effectiveness of a 
Pneumococcal Conjugate Vaccine in Acute Suppurative Otitis Media: A Randomized Controlled Trial in 
Bangladeshi Infants.”  The analysis described in the manuscript was approved by the Cincinnati 
Children’s Hospital Medical Center Institutional Review Board. The other authors listed for the 
manuscript are S.B. OmerD, S.E. ArifeenA, R. RaqibA, R.F. BreimanE, and K. Zaman.A They were all 
involved in the design and implementation of the initial Mother’s Gift trial and had peripheral 
involvement in the manuscript.  Statistical analysis for the manuscript was performed by Caitlin Dodd.C  
The results for the primary outcomes from the Mother’s Gift trial have not been published yet.  Several 
articles describing the results of other secondary analyses of the Mother’s Gift trial data have been 
published, and they are included in the reference list.16-25 
AInternational Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh 
BBloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA 
CCincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA 
DRollins School of Public Health, Emory University, Atlanta, Georgia, USA 
ECenters for Disease Control and Prevention, Atlanta, Georgia, USA  
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serotypes in its 2012 immunization recommendations.26  Since the demographic, geographic, and 
population health characteristics of Bangladesh and India are very similar, if this analysis finds 
that the 7-valent PCV significantly decreases AOM with TM perforation among infants in 
Bangladesh, then that finding would be reasonably generalizable to India.  Since S. pneumoniae 
causes about 25–62% of AOM,14,27,28  finding that the PCV substantially decreases AOM with 
TM perforation could suggest that the PCV is effective against an adequate number of S. 
pneumoniae serotypes in the region.  That evidence could potentially help convince policy 
makers in India to add the PCV to its Universal Immunization Program (UIP). 
2) This analysis is also the first to use data from a randomized trial to investigate the 
effect of the PCV on otitis media in a country with a high burden of suffering due to otitis media.  
Both Bangladesh and India certainly meet this criterion.29-31  Otitis media causes an estimated 
3,500 deaths and 4.7 million DALYs worldwide every year.1,2  A substantial portion of those 
occur in the South Asia WHO subregion, which is composed of Afghanistan, Bangladesh, 
Bhutan, India, Nepal, and Pakistan.29,32  The South Asia subregion has 23% of the world’s 
population, but it accounted for an estimated 48% of the deaths due to otitis media in 2005.29  
The subregion also accounted for astounding proportions of the hearing impairment (HI) caused 
by otitis media, which were an estimated 75% of the moderate HI, 85% of the severe HI, and 
93% of the profound HI due to otitis media.29,33  Much of this burden of suffering due to otitis 
media in South Asia likely comes from India, since it has 75% of the subregion’s population.  
(See Appendix B, for more information about the burden of suffering due to otitis media.) 
Three previous RCTs investigated the effect of PCV administration to infants on otitis 
media, and they found relative risk reductions of 6–34% in the incidence of AOM.28,34,35  
However, those studies were in high-income countries that have a much lower incidence and 
8 
 
prevalence of otitis media.29,36  If this analysis finds that the PCV decreases AOM with TM 
perforation among infants in Bangladesh, it would provide new evidence that the PCV might 
prevent substantial morbidity and mortality in India by decreasing deaths, hearing impairment, 
and other complications due to otitis media.  That potential finding, in combination with the 
existing evidence that the PCV decreases IPD in children, might also help convince policy 
makers to add the PCV to India’s UIP. 
METHODS 
 
Study Design  
This study compares the effects of the PCV and Haemophilus influenzae type b (Hib) 
conjugate vaccine on AOM with TM perforation in infants.  It is a randomized, comparison-
controlled, parallel group study, involving the secondary analysis of data that were originally 
collected in Bangladesh in 2004 and 2005 for the Mother’s Gift trial.  Although the data for this 
analysis were collected prospectively, the outcomes it evaluates were chosen retrospectively.  
The Mother’s Gift trial collected a large amount of interview data to monitor for possible adverse 
effects.  The decision to pursue this secondary analysis was made after a post-hoc examination of 
the interview data uncovered a significant difference in the reports of AOM with TM perforation 
between infants who received the PCV and Hib vaccine.  The protocol for this secondary 
analysis was evaluated by the institutional review board (IRB) at the University of North 
Carolina at Chapel Hill, which judged that it did not require formal IRB approval because it used 
de-identified data that contained no identifiable private information.  
This analysis is comparison-controlled and uses the Hib vaccine as the comparator, so it 
is not a placebo-controlled study.  However, the consideration of the analysis’ potential 
relevance in the introduction and  the interpretation of the results in the discussion generally 
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regard the Hib vaccine as a quasi-placebo because its effect on otitis media is very small.28,37  
The rationale for this is further explained in the discussion section on pages 22-23 below, in the 
subsection entitled “Limitations due to Study Design.”  
Data Source 
The Mother’s Gift trial (ClinicalTrials.gov number NCT00142389), investigated whether 
the immunization of pregnant women with the pneumococcal polysaccharide vaccine (PPV) 
might decrease the immunogenicity of the PCV among their infants or cause other adverse 
effects.  Its primary and secondary outcomes were adverse reactions to the vaccines and infants’ 
levels of anti-pneumococcal immunoglobulin G (IgG) antibodies at 20 weeks and 12 months of 
age.38  The results of the pre-specified primary and secondary outcomes from the Mother’s Gift 
trial have not yet been published.  Several articles describing analyses of Mother’s Gift trial data 
have been published, and they are included in the reference list.16-25  The Mother’s Gift trial  
investigated whether maternal PPV immunization interferes with the immunogenicity of the 
PCV among infants or  causes other significant negative adverse effects.  If the trial finds that 
maternal PPV immunization does neither of those things, then its authors have planned to 
perform a larger study to investigate the effect of maternal PPV immunization on IPD in infants 
(especially during the first several weeks of life before infants receive their initial doses of the 
PCV).  
The Mother’s Gift trial protocol was reviewed and approved by the IRBs at the 
International Centre for Diarrheal Disease Research, Bangladesh (ICDDR,B) and the Bloomberg 
School of Public Health at Johns Hopkins University.  Monitoring for adverse events during the 
Mother’s Gift trial was conducted through the weekly interviews described below.  An 
independent data and safety monitoring board and the two above IRBs reviewed all possible 
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severe adverse events.  Use of study vaccines was approved by the Directorate of Drug 
Administration of the Government of the People's Republic of Bangladesh. 
Participants 
Maternal participants were recruited into the Mother’s Gift trial from three urban, 
antenatal clinics in Dhaka, Bangladesh.  All women in their third trimester of pregnancy who 
attended one of the three antenatal clinics between August 2004 and May 2005 were screened for 
participation in the study.  Inclusion criteria were women who were 18-40 years of age, had a 
normal medical and obstetric history, and planned to remain in Dhaka for one year after delivery.  
Exclusion criteria were the receipt of a pneumococcal vaccine in the previous 3 years, a 
contraindication to getting a study vaccine, a last menstrual period (LMP) date not consistent 
with the clinical examination, and a previous history of a systemic disease, pregnancy 
complication, preterm delivery, abortion, birth with a congenital anomaly, or allergic reaction to 
a vaccination. 
Sample size calculations performed for the Mother’s Gift trial deemed that 336 mother-
infant pairs would be necessary to detect a difference in the mean pneumococcal antibody titers 
of the infant participants (based on reported local antibody variance data, a 2-sided α = 0.05, a β 
= 0.20, and an assumed 25% attrition rate).16  No sample size calculations were performed for 
this secondary analysis. 
Interventions and Randomization 
 Upon enrollment in the Mother’s Gift trial, the pregnant women were randomly assigned 
to receive either the PPV (23-valent, Pneumovax®, Merck) or the inactivated influenza vaccine 
(Fluarix®, GlaxoSmithKline).  At that time, their future infants were assigned to receive either 
the PCV (7-valent, Prevnar®, Wyeth) or the Hib conjugate vaccine (PRP-T, Hiberix®, 
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GlaxoSmithKline).  For this analysis, the infants were divided based on the vaccine they received 
into the PCV group and the Hib vaccine group.  Randomization was blocked to achieve similar 
numbers of each of the four possible maternal-infant vaccine combinations (Table 1).  As a 
result, in both the PCV group and the Hib vaccine group, approximately half of the infants had 
mothers who received the PPV, and approximately half had mothers who received the influenza 
vaccine (Figure 1).  Of note, the comparison vaccines (influenza and Hib) were included in the 
original Mother’s Gift trial because the ICDDR,B IRB would not approve a placebo-controlled 
trial and required that all participants receive the benefit of some type of vaccine in exchange for 
their participation in the trial. 
Randomization was performed using a computer-generated sequence that was developed 
centrally before study enrollment began.  Randomization was stratified by the three antenatal 
clinics.  Sequentially-numbered, opaque envelopes with the vaccine assignments were provided 
to each clinic.  Clinic staff who administered the vaccines were aware of the vaccine and group 
assignments, but they were not involved with the measurement of study outcomes.  Other clinic 
staff, the participants and their families, and the study staff who collected the data were blinded 
to vaccine and group assignments. 
Pregnant women received one dose of their assigned vaccine (PPV or influenza vaccine) 
during the third trimester of pregnancy.  Infants were assigned to receive three doses of their 
study vaccine (PCV or Hib vaccine) at 6, 10, and 14 weeks of age.  All vaccine doses were 
administered through intramuscular injection.  All study vaccines were purchased from the 
manufacturers. 
Outcomes and Measurement  
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The outcome data in this analysis were collected during weekly interviews with infants’ 
mothers (or other knowledgeable caregivers) between 6 and 24 weeks of age.  According to the 
Mother’s Gift trial protocol, interviews were to occur every other week from birth to 6 weeks of 
age, then every week from 6 to 24 weeks of age.  This analysis does not include data collected 
prior to 6 weeks of age because that was before any of the infants received the PCV or Hib 
vaccine.  Although additional interviews occurred between 25 and 37 weeks of age, these 
interviews were excluded from the analysis because they were not performed consistently for all 
infants and because they were not part of the original trial protocol. 
The weekly interviews included questions about infant feeding, illness symptoms, and 
treatments given to the infants.  The questions most relevant to this analysis were those 
concerning respiratory and ear infections and antibiotic use.  The interviewees were asked every 
week if the infant had had an ear problem during the last week.  If the answer was yes, they were 
also asked if it involved drainage from one ear, both ears, or neither ear.  The interviewees were 
also asked if the infant had had a respiratory illness during the last week.  If the answer was yes, 
they were asked if it involved cough, runny nose, sore throat, difficulty breathing, and/or 
provider-diagnosed pneumonia.  Whenever an ear problem or respiratory illness was reported, 
the interviewer asked if any treatments were given for the illness.  The types of medications 
(antibiotic, antihistamine, antipyretic, etc.) were recorded, but the specific names of the 
medications were not recorded. 
For this analysis, all reports of ear drainage were considered to represent purulent 
otorrhea due to AOM with TM perforation.  The interview questions about ear problems and ear 
drainage did not differentiate between one day and seven days of symptoms during the last week.  
Never the less, this analysis assumes that consecutive weekly reports of ear drainage are assumed 
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to be all part of one episode, as opposed to two separate episodes with complete resolution in 
between.  This is a reasonable assumption given the nature and clinical course of most ear 
infections and given that ear drainage that seems to resolve and then recur within a week is much 
more likely to be related to the initial AOM with TM perforation episode than to a new episode.  
This analysis did not attempt to calculate durations for episodes in days or weeks because of the 
imprecision inherent in the way the data were collected.  Here are 3 examples that illustrate this 
concept.  1) If an infant had a 6 day episode of ear drainage that all occurred within one 
interview week, then that infant’s 6 day episode would have one positive weekly report.  2) If an 
infant had a 2 day episode of ear drainage, of which 1 day occurred during one interview week 
and 1 day occurred during the next, then that infant’s 2 day episode would have 2 positive 
weekly reports.  3) If an infant had a 12 day episode of ear drainage, of which 6 days occurred 
during one interview week and 6 days occurred during the next, then that infant’s 12 day episode 
would have 2 positive weekly reports.  As a result of this imprecision, this analysis does not 
calculate the duration of episodes.  Instead episodes are compared by their number of weekly 
reports, which preserves the vagueness of the data and most closely represents how the data were 
collected.  
For weeks when infants had positive reports of AOM with TM perforation, they were 
considered to have received antibiotics for that infection if they were given an antibiotic intended 
to treat the AOM with TM perforation or an antibiotic intended to treat a respiratory illness.  This 
is reasonable because the same antibiotics are generally prescribed for both respiratory and ear 
infections, since the bacteria that commonly cause both types infections in children are largely 
the same. 
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The weekly interviews were conducted by field workers, who were trained and overseen 
by study supervisors.  The interviews were performed over the telephone, at an infant’s home, or 
at one of the study clinics.  Weekly interviews at homes or in clinics included weight, height and 
mid-upper arm circumference (MUAC) measurements.  Maternal height, weight, and MUAC 
were measured at the time of delivery.  Maternal participants were interviewed about their 
baseline health and demographic characteristics soon after their enrollment in the study.  They 
were interviewed about their deliveries within one week of their occurrence in almost all cases.  
Data on the number of vaccines received by infants were recorded in the clinics where the 
vaccines were given.  Those data were not available for this analysis, but the weekly interviews 
included caregiver reports of vaccine administration, so those data were used instead. 
Statistical Analysis 
Baseline characteristics were measured for each group.  Means or percentages were 
calculated as appropriate for each characteristic.  Outcomes were reported as percentages and 
frequencies, and their statistical significance was determined by calculating the confidence 
intervals for the risk differences using standard formulae.39  Possible confounders were evaluated 
using the same approach.  The average number of weekly reports per episode of AOM with TM 
perforation for each vaccine group were compared using the Wilcoxon rank-sum test performed 
using Stata® 12 software.40  Antibiotic treatment during the first week of an episode was 
identified as a possible confounder.  The combined influence of vaccine group and antibiotic 
treatment on the number of weekly reports per episode was evaluated using the generalized 
linear model procedure in SAS® 9.4 software.41 
RESULTS 
Participants 
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823 pregnant women were screened for study eligibility.  340 of them were enrolled in 
the study and randomized along with their future infants.  The reasons why women did not enroll 
in the study are listed in Figure 2.  After enrollment, but prior to the intervention of interest in 
this analysis, 12 infant participants (6 from each group) left the study.  No outcome data were 
collected for these infants.  Their data were not included in Table 2, which compared baseline 
participant characteristics.  Figure 2 lists the reasons they left the trial, if they are known.  Due to 
the departure of these 12 infants, there were 328 infants still in the trial when the infant vaccine 
portion of the intervention began.  165 of the remaining infants were in the PCV group, and 163 
were in the Hib vaccine group. 
Baseline health, biometric, and demographic characteristics of these 328 infants and their 
mothers are listed in Table 2.  For most characteristics the differences between the PCV and Hib 
vaccine groups were small.  For three characteristics there was a relative difference of >15% 
between the two groups.   These were gestational age of <38 weeks, birth by cesarean section, 
and secondhand smoke exposure in the home.  Each of these characteristics was more frequent in 
the PCV group, with absolute differences of 4.1%, 14%, and 6.2% respectively.  Tests for 
statistical significance for these differences were not performed. 
Intervention  
Although the infant participants were all supposed to receive three doses of their assigned 
vaccine, it seems that only 9% in the PCV group and 7% in the Hib vaccine group received 
exactly three doses.  The numbers of infants in each group receiving 0, 1, 2, 3, and 4 doses of 
their assigned vaccine are listed in Figure 2.  As is noted above, these data are from caregiver 
reports during the weekly interviews and not from the clinic records, which were not available 
for this analysis. 
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Data Collection 
According to the Mother’s Gift protocol, interviews about the infants’ health were to 
occur weekly between 6 and 24 weeks of age.  Only 1.8% (3/165) of infants in the PCV group 
and 3.1% (5/163) in the Hib vaccine group were lost to follow up during data collection.  After 
adjusting for the interviews missed due to these 8 infants that were lost to follow up, the 
expected number of weekly interviews was 3,114 for the PCV group and 3,048 for the Hib 
group.  Interview data were collected for 99% of these expected weeks for both the PCV group 
(3,086/3,114) and the Hib vaccine group (3,020/3,048).  Even though there was a high level of 
data completeness in both groups, not all of the data were collected on time.  When one or more 
interviews did not occur during the assigned week, data for multiple weeks were often collected 
at the next interview.  2.3% (71/3,086) of PCV group interviews and 2.9% (87/3,020) of Hib 
vaccine group interviews were conducted at least one week late.  The degree of lateness per 
group is further specified in Table 3.  No weekly reports of AOM with TM perforation are from 
interviews that were ≥1 week late. 
Interviews occurred in three different settings.  Altogether, 47% of the weekly interviews 
were performed over the telephone, 43% were performed at infants’ homes, and 10% were 
performed at one of the study clinics.  Table 4 lists the number of interviews for each type by 
vaccine groups, and it also lists the positive weekly reports of AOM with TM perforation for 
each interview type by group.    
 Even though the weekly interviews were supposed to end at 24 weeks of age, about two 
thirds of infants in both groups had at least one interview after 24 weeks.  However, there were 
considerably fewer interviews for each week after 24 weeks of age, such that only 7% of infants 
had interviews after 28 weeks.  The numbers of interviews after 24 weeks were similar for each 
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group with 246 for the PCV group and 281 for the Hib vaccine group.  Investigators from the 
original trial believe that the weekly interviews may have continued for some participants 
beyond 24 weeks of age due to requests by the families.  Three weekly reports of AOM with TM 
perforation occurred after 24 weeks, and they were not included in the data analysis.  All three 
were in the Hib vaccine group.  One report was on week 25 in an infant who had not had any 
prior reports of ear issues.  The other two reports were on weeks 25 and 26 in an infant who had 
previous positive reports on weeks 15-19, 23, and 24 (Row 8 of Hib vaccine group in Figure 3). 
 Interview data prior to 6 weeks of age were excluded from the analysis because none of 
the infants received a study vaccine prior to 6 weeks of age.  There were no weekly reports of 
AOM with TM perforation prior to 6 weeks. 
Outcomes 
In the PCV group, there were 13 positive weekly reports of AOM with TM perforation 
among the 165 infants, who had a total of 3,086 weekly interviews.  The 13 weekly reports come 
from 9 infants who had a total of 11 episodes.  In the Hib vaccine group, there were 31 positive 
weekly reports of AOM with TM perforation among the 163 infants, who had a total of 3,020 
weekly interviews.  The 31 weekly reports come from 10 infants who had a total of 12 episodes.  
These data are listed in Table 5 and depicted visually in Figure 3 by vaccine group, week, and 
infant. 
 The percentage of weeks with positive reports of AOM with TM perforation was 0.4% 
for the PCV group and 1.0% for the Hib vaccine group; the risk difference of 0.6% between the 
groups was statistically significant (95% C.I. 0.2% – 1.0%, Table 5).  However, the percentage 
of infants with one or more weekly reports of AOM with TM perforation was similar for both 
groups at 5.4% in the PCV group and 6.1% in the Hib vaccine group, with a risk difference of 
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0.7%, which was not statistically significant (95% C.I. -6% – 4%, Table 5).  The percentages of 
weekly interviews with a new episode were also similar for both groups at 0.36% for the PCV 
group and 0.40% for the Hib vaccine group,  with a risk difference of 0.04%, which was not 
statistically significant (95% C.I. -0.3% – 0.3%, Table 5).   
 Review of the characteristics of the 19 infants with ≥1 episode of AOM with TM 
perforation revealed that 16 male infants had an episode of AOM with TM perforation compared 
to only 3 female infants (RR = 3.9, 95% C.I. 1.2 – 13).  This sex difference was similar in both 
groups and is further detailed in Table 6.  In the PCV group there were 8 males and 1 female 
with AOM with TM perforation.  In the Hib vaccine group there were 8 males and 2 females 
with AOM with TM perforation.  
There were similar numbers of episodes of AOM with TM perforation per group, but the 
total number of weekly reports was significantly higher in the Hib vaccine group, giving it more 
weekly reports per episode.  Table 7 shows the average number of weekly reports of AOM with 
TM perforation per episode, which was 1.2 for the PCV group and 2.6 for the Hib vaccine group.  
For both groups the number of weekly reports per episode does not have a normal distribution 
due to substantial positive skew.  As a result, the Wilcoxon rank-sum test was used and it found a 
statistically significant difference with a p value of 0.005.  The median number of reports per 
episode and the /z/ statistic value are also reported in Table 7.   
The finding of similar numbers of episodes in both vaccine groups suggests that the PCV 
does not prevent episodes of AOM with TM perforation when compared to the Hib vaccine.  
However, the statistically significant difference in the number of weekly reports per episode 
suggests the possibility that PCV might decrease the duration of episodes of AOM with TM 
perforation compared to the Hib vaccine.  In this analysis there were 23 episodes per 328 infants, 
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which is one episode per 14.3 infants.  The findings above suggest that immunizing 14.3 infants 
with the PCV (compared to with the Hib vaccine) might not prevent any episodes of AOM with 
TM perforation between 6 and 24 weeks of age, but it might decrease the length of one episode 
during that time from about 2.6 weeks to 1.2 weeks. 
Possible Confounding Variables 
 The data in this study are from an RCT, which appears to have had a large enough sample 
for effective randomization based on the results in Table 2.  However, there were only 19 infants 
who had an episode of AOM with TM perforation, which is much smaller than the 328 infants 
whose data were considered in the full analysis.  Consideration of possible confounders is 
appropriate in any secondary analysis of data from an RCT, but it is essential in this analysis 
since the statistically significant finding comes from such a small subset of the study sample. 
 Of the variables and characteristics measured in the original analysis, the two that are 
most likely to lead to an increased risk of longer episodes of AOM with TM perforation are 
exposure to secondhand smoke and antibiotic treatment.42,43  Among the infants with one or 
more weekly reports of AOM with TM perforation, 44% in the PCV group and 50% in the Hib 
vaccine group were exposed to secondhand smoke at home, for which the risk difference of 6% 
was not statistically significant (95% C.I. -39% – 50%, Table 8).  Similarly, the percentage of 
episodes occurring among infants with secondhand smoke exposure was 46% in the PCV group 
and 55% in the Hib vaccine group smoke, for which the risk difference of 9% was not 
statistically significant (95% C.I. -24% – 41%, Table 8).  Given that the difference in 
secondhand smoke exposure between the two groups lacked statistical significance and was 
small in magnitude, it was not considered further as a possible confounder. 
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 Among the infants with one or more weekly reports of AOM with TM perforation, there 
were considerable differences in antibiotic treatment between the two groups.  The percentage of 
weeks when both AOM with TM perforation and antibiotic treatment were both reported was 
85% in the PCV group and 52% in the Hib vaccine group, for which the risk difference of 33% 
was statistically significant (95% C.I. 7% – 59%, Table 9).  Similarly the percentage of episodes 
of AOM with TM perforation when antibiotic treatment was reported during the first week of the 
episode was 82% in the PCV group and only 25% in the Hib vaccine group, for which the risk 
difference of 57% was statistically significant (95% C.I.  23% – 90%, Table 9).  These results 
established that despite randomization antibiotic treatment was substantially and significantly 
different among the infants with episodes of AOM with TM perforation in the two groups.  In 
general, antibiotic treatment is much more effective at decreasing the duration of AOM with TM 
perforation when it begins at the earlier stages of the infection.  In addition, it is difficult to 
compare and analyze antibiotic treatment during different weeks of an episode in a way that is 
meaningful both clinically and statistically.  As a result, further investigation into antibiotic use 
as a confounder focused on the effect of treating or not treating with antibiotics during the first 
week of episodes of AOM with TM perforation.  A multivariate analysis using a generalized 
linear model was used to investigate whether the differences in antibiotic treatment during the 
first week of episodes could account for the difference in the number of weekly reports per 
episode between the two groups. 
 The generalized linear model found that when the influence of both vaccine type and 
antibiotic treatment during the first week were considered, neither had a statistically significant 
effect on the number of weekly reports per episode of AOM with TM perforation.  The estimate 
value for vaccine in Table 10 indicates that the model found an average of 1.1 more weekly 
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reports per episode among infants in the Hib vaccine group compared to those in the PCV group, 
but this was not statistically significant (t = 1.7, p = 0.10).  The estimate value for antibiotic 
treatment in Table 10 indicates that the model found an average of 0.6 more weekly reports for 
episodes that were treated with antibiotics during the first week compared to those that were not, 
but this was also not statistically significant (t = 1.0, p = 0.33). 
Adverse Events 
 Data regarding adverse events were collected through interviews that occurred about one 
week after each vaccine was administered.  Additional adverse events were identified through 
appointments at the study clinics for illnesses and for check-ups.  Those data were not available 
for this analysis.  However, a previously published secondary analysis of the same data found 
that there were 18 infants who were hospitalized between 5 and 24 weeks for the following 
reasons: gastroenteritis (6), pneumonia (5), septicemia (5), and meningitis (2).16  That analysis 
was concerned with maternal vaccine groups, so it did not report which vaccines the hospitalized 
infants received. 
DISCUSSION 
Main Findings 
Similar percentages of infants experienced episodes of AOM with TM perforation in both 
the PCV and Hib vaccine groups.  The incidence of new episodes was also similar for both 
groups.  These findings suggest that among Bangladeshi infants less than 24 weeks of age the 
PCV, when compared to the Hib vaccine, does not decrease the number of infants who get AOM 
with TM perforation.  They also suggest that it does not decrease the number of episodes they 
experience.  However, infants in the PCV group, compared to those in the Hib vaccine group, 
had less than half as many weekly reports per episode and less than half the rate of weekly 
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reports overall.  Before adjusting for confounding, these differences were statistically and 
clinically significant, such that immunizing 14 infants with PCV might decrease the duration of 
one episode of AOM with TM perforation prior to 24 weeks of age from 2.6 weeks to 1.2 weeks.  
However, after adjusting for antibiotic use during the first week of episodes, the difference in 
weekly reports per episode was no longer statistically significant (p = 0.10).   
A multivariate analysis using a generalized linear model calculated how vaccine type and 
antibiotic use during the first week of an episode affected the number of weekly reports per 
episode.  The model estimated that the PCV was associated with a 1.1 week decrease compared 
to the Hib vaccine and that antibiotic use was associated with a 0.6 week decrease.  Even though 
these estimates were not statistically significant, they are somewhat consistent with the findings 
of other studies.  A meta-analysis found that antibiotic treatment for children with AOM 
decreased occurrences of TM perforation (number needed to treat: 33),42 so it is plausible that 
antibiotics might also decrease the duration of ear drainage due AOM with TM perforation.  
Three large RCTs have found that the  PCV caused a relative risk reduction (RRR) of 6˗34% in 
the incidence of AOM episodes in children, so it is plausible that the PCV might also decrease 
the duration of episodes of AOM with TM perforation.28,34,44 
Strengths 
This analysis has several strengths.  Its data come from a blinded, randomized trial.  
Furthermore, the comparison of the baseline participant characteristics in Table 2 indicates that 
randomization was effective overall.  The characteristics that differed most between the two 
groups were prematurity, cesarean section birth, and secondhand smoke exposure.  Since 
prematurity and cesarean section birth are not known risk factors for otitis media, the modest 
differences for those characteristics are unlikely to have substantially affected the results.  
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Secondhand smoke exposure is a known contributor to otitis media, but the 6.2% difference (11 
more infants in the PCV group) is also unlikely to have substantially affected the results.  A 
recent meta-analysis estimated that the increased risk of otitis media due to secondhand smoke 
exposure was relatively small with an odds ratio of 1.37 (95% CI, 1.25-1.50).45  Based on this 
odds ratio and the incidence of episodes in the analysis, the 6.2% difference in secondhand 
smoke exposure would contribute an estimated 0.3 additional episodes to the PCV group, which 
would not have significantly affected the results.  In addition, there were similar percentages of 
secondhand smoke exposure among infants with AOM with TM perforation in both the PCV and 
Hib vaccine groups (Table 8). 
Additional strengths of this analysis are that data were collected prospectively and that 
there were low numbers of infants lost to follow up and a high level of data completeness.  
Specifically, 99% of weekly interviews were completed, 2.4% of infants were lost to follow up 
after the intervention began, and 5.9% of infants total were lost to follow up.  Data completeness 
and number of infants lost to follow up were similar for both groups. 
Limitations 
 This analysis has many limitations that primarily involve issues with study design, 
measurement, recordkeeping, and implementation.  The limitations are grouped into those 
categories and described below. 
Limitations due to Study Design 
The data in this analysis were collected for the Mother’s Gift trial, which did not have a 
true control group.  Due to a request by the ICDDR,B IRB, infants in the non-experimental 
group were also given a vaccine.  Trial authors chose the Hib conjugate vaccine, Hiberix® 
(GlaxoSmithKline), to be the quasi-placebo for the control group.  Other studies have also given 
24 
 
quasi-placebos to control group participants,46 including a similar study that investigated the 
effect of PCV on AOM, using the hepatitis A vaccine as a quasi- placebo.28  The use of the Hib 
vaccine as a quasi-placebo is a limitation of this analysis because Hib is a known pathogen in 
otitis media.  However, it is a minor pathogen, which makes it less likely to have a substantial 
effect on the results, as is outlined in detail below. 
Haemophilus influenzae bacteria can be divided into two kinds: unencapsulated (which 
are referred to as nontypeable) and encapsulated (which are divided into serotypes a–f, with Hib 
being serotype b).  Nontypeable Haemophilus influenzae (NTHi) strains mostly cause infections 
of the upper and lower respiratory tract, including otitis media.  NTHi are responsible for about 
12-30% of cases of otitis media, second only to Streptococcus pneumoniae.14,27,28,37  The Hib 
vaccine is not effective against NTHi and the infections they cause.  The immunogenic 
component of the Hib conjugate vaccine is polyribosylribitol phosphate, the polysaccharide 
contained in the Hib capsule. Since NTHi do not have a capsule, the Hib conjugate vaccine in 
not effective on them. 
Hib was a common cause of invasive infections such as meningitis, pneumonia, septic 
arthritis, cellulitis, and bacteremia prior to widespread Hib vaccination.  In populations not 
immunized against Hib, it still is a common cause of those infections.  Hib is a minor cause of 
otitis media, responsible for 0.6% of episodes in populations immunized against Hib and for 1-
3% of episodes prior to widespread Hib vaccination.27,28,37  Since the Hib vaccine is not effective 
against NTHi and since Hib is responsible for a very small percentage of otitis media episodes, 
the Hib vaccine is considered as a quasi-placebo in the interpretation of this analysis.  If using 
the Hib vaccine as a quasi-placebo were to affect the results, it would most likely cause a small 
decrease in the differences in otitis media between the two groups, creating a small bias toward 
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the null hypothesis.  Although it is reasonable to consider the Hib vaccine as a quasi-placebo, 
this presumption is vulnerable to an unknown degree of uncertainty, given the complexity and 
incomplete understanding on a microbiological level of exactly how and why bacterial ear 
infections develop.  
The small sample size and short duration of observation limited the potential of this 
analysis to detect the effect of the PCV on AOM with TM perforation.  The total observation 
time for this analysis was 117 child-years.  By contrast, the three other randomized trials that 
have investigated the effect of the PCV on otitis media had 2,400 child-years, 10,000 child years, 
and 130,000 child years.28,34,44  The relatively short total period of observation resulted in a small 
number of episodes in the analysis and limited its power to detect differences in both the 
incidence and duration of episodes of AOM with TM perforation.    
Reliable data collection for this analysis ended at about 5.5 months (24 weeks) of age.  
This was inappropriately early for the outcome of interest, and it further limited the ability of the 
analysis to detect the effects of the PCV.  Studies in both high and low-income countries have 
found that the incidence of AOM with and without TM perforation is greatest between 6˗24 
months of age.34,47  The 0˗6 month period accounts for only about 15-17% of episodes of AOM 
between 0˗24 months of age and about 10% of episodes between 0˗48 months of age.34,47  Only 
having reliable data through 5.5 months of age meant that the analysis lacked data for the periods 
when its participants would experience the vast majority of episodes of AOM with TM 
perforation. 
 This analysis was undertaken because a post-hoc examination of the interview data 
uncovered a statistically significant difference in the weekly reports of AOM with TM 
perforation the PCV and Hib vaccine groups.  This increases the possibility of that finding being 
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due to a type 1 error.  However, that difference was not statistically significant after adjustment 
for confounding due to discrepancies in antibiotic use between the two groups.  As a result, type 
1 error ended up not being a concern for this analysis.   
Limitations due to Measurement Issues 
Secondary analyses are vulnerable to measurement errors when the conceptualization and 
measurement of outcome variables are substantially different from their purposes in the original 
study.  This was especially true of this analysis’ use of caregiver report of ear drainage to 
represent AOM with TM perforation.  This conceptualization increased the likelihood of both 
underdiagnosis and overdiagnosis.   
 Diagnosis of AOM with TM perforation by caregiver report would lead to underdiagnosis 
when caregivers fail to recognize or report ear drainage.  This analysis had a much lower 
incidence of AOM with TM perforation than a comparable study, and it also had a significant 
difference in incidence between male and female infants.  Underdiagnosis was a likely 
contributor to both of these findings. 
The incidence of AOM with TM perforation in this analysis was much lower compared to 
a study in rural Bangladesh by Roy et al., which used more deliberate measurement techniques.  
That study found an incidence of 0.54 episodes per child year between 0-6 months.  This analysis 
found an incidence of 0.20 episodes per child year between the similar age range of 6-24 weeks.  
This discrepancy is most likely due to the more sensitive measurement techniques in the Roy et 
al. study, in which interviews and otoscopy were performed every 4 days with the explicit 
purpose of screening for AOM both with and without perforation.  An actual difference in 
incidence between urban and rural populations may have also contributed to the discrepancy 
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between the two studies.  Differences in incidence between urban and rural populations have 
been described in other studies and attributed to environmental and socio-economic factors.48-50   
The analysis found that females were 3.9 times less likely than males to have an episode 
of AOM with TM perforation (Table 6).  A similar phenomenon was noted in another study in 
Bangladesh, which found that caregivers were 1.7 times less likely to seek medical treatment for 
their female children than their male children.51  Underdiagnosis of female infants, as opposed to 
overdiagnosis of males, is the more likely explanation for this finding, given the relatively low 
overall incidence of episodes of AOM with TM perforation in this analysis.  The difference in 
incidence between males and females could also be partially explained by an actual difference in 
the epidemiology of otitis media.  Roy et al. found that the incidence of AOM with TM 
perforation was similar for males and females in rural Bangladesh, but they did find that males 
were more likely to have recurrent episodes.47  Several large epidemiologic studies in high-
income countries have found that males are at a slightly increased risk for otitis media.34,52-55  
Although this might partially explain the large difference in incidence between males and 
females in this analysis, it is very unlikely that it would explain all or even most of it. 
Using caregiver report of ear drainage to represent AOM with TM perforation could also 
lead to overdiagnosis because it does not distinguish AOM with TM perforation from the other 
common causes of ear drainage in infants, such as otitis externa, foreign body in the ear canal, 
and normal drainage of cerumen.  Table 11 describes the expected findings for each of these 
conditions.  In clinical practice, the determination of the specific cause of ear drainage is based 
on a combination of the appearance of the ear drainage, otoscopy, and clinical history.  Had the 
weekly interviews included questions about the ear drainage and other relevant symptoms, the 
analysis could have more accurately determined when ear drainage was AOM with TM 
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perforation and when it was not.  For example, cerumen could have been easily excluded as the 
cause of ear drainage with a few simple questions about the appearance, amount, duration, and 
frequency of the ear drainage.  Overall, using caregiver report of the presence of ear drainage for 
diagnosis increased the possibility that this analysis overestimated the incidence of AOM with 
TM perforation.   
Relying on caregiver report of ear drainage to diagnose AOM with TM perforation would 
not necessarily lead to a differential bias in the results because this approach appears to have 
been employed  equally in both groups.  However, its potential to cause substantial measurement 
inaccuracies could still bias the results.  For example, the infants represented in rows 8 and 10 in 
Figure 3 accounted for 15 of the 31 weekly reports of AOM with TM perforation in the Hib 
vaccine group, which was almost all of the difference in weekly reports between the two groups 
(See Table 5.).  If instead of having AOM with TM perforation, one of these two infants had 
frequent ceruminous ear drainage and the other infant actually had otitis externa or a foreign 
body in his/her canal, then overdiagnosis could be the source of almost all the difference between 
the groups.  Normally adequate randomization protects against this sort of phenomenon.  
However, when the potential for measurement error is this high and when only two participants 
account for almost all of the difference between the two groups, randomization may not prevent 
measurement errors from biasing the results. 
Other studies diagnose AOM with or without TM perforation using a variety of 
techniques, which generally seem more reliable than caregiver report of ear drainage.  Perkins et 
al. gave basic physical diagnosis training to high school-educated community health workers 
(CHWs) in Kenya.56  After their training, the CHWs could accurately diagnose purulent ear 
drainage with a specificity and sensitivity of ≥ 95% compared to physician diagnosis.56  In the 
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study in rural Bangladesh by Roy et al. that is described above, CHWs were trained for 2 weeks 
in clinical diagnosis of AOM including otoscopy, and then they diagnosed AOM with TM 
perforation based on the presence of purulent ear drainage.47  Studies in high-income countries 
have based diagnosis on a combination of ear fluid cultures and physician examination using 
standardized criteria.14,28,35  These different techniques are probably much more accurate and 
reliable than those used in the current analysis.  
One other limitation of this analysis due to a measurement issue is interview lateness.  
2.6% of the data were collected during interviews that involved recall of information from 
greater than 7 days prior.  Since the average lateness of the interviews was similar in both 
groups, this should not cause a differential bias.  None of the reports of AOM with TM 
perforation were from late interviews, so lateness did not contribute to overdiagnosis.  However, 
since some caregivers may have forgotten about episodes of ear drainage when  more than a 
week passed between the episode and the next interview, late interviews may have contributed to 
underdiagnosis. 
Limitations due to Recordkeeping and Implementation 
 At the time of this analysis some of the important data from the original Mother’s Gift 
trial were unable to be located.  The most important of these were clinic records, which had 
information about when infants received their vaccines and experienced adverse events, such as 
illnesses requiring hospitalization.   
Caregiver reports of vaccine administration in the weekly interviews were used in place 
of the missing clinic records.  It is unclear if these reports are similar in accuracy to the clinic 
data or not.  Figure 2 lists how many infants received each number of doses of their assigned 
vaccine.  The numbers for both groups were remarkably similar.  All infants were supposed to 
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receive three doses of their assigned vaccine.  However, according to the caregiver reports, 
among the infants in the PCV group 10% (17/165) received three doses and 71% (116/165) 
received two doses.  Three doses are needed to generate protective antibody titers against all 
serotypes of the 7-valent PCV, but two doses do provide protection against 3 serotypes and 
partial protection against 2 additional serotypes.  This apparent suboptimal adherence to the 
intervention has the potential to cause a bias toward the null hypothesis with respect to the effect 
of the PCV on AOM with TM perforation.  Many previous studies have confirmed the safety of 
the PCV and Hib vaccines.34,44,57-59  As a result, there is no reason to expect any differences in 
hospitalizations or other adverse events between the two groups.  Never the less, it is unfortunate 
that actual data on adverse events was not available for this analysis. 
Interpretation and Generalizability of the Results 
The results of this analysis suggest that the 7-valent PCV does not affect the incidence or 
duration of episodes of AOM with TM perforation among infants in Bangladesh.  However, 
there is a high degree of uncertainty in these findings due to the problems with study design, 
measurement, and implementation described above.  Due to these issues, the analysis likely has 
poor internal validity and subsequent low generalizability, such that its results should not be used 
to draw conclusions about the effect of the PCV on otitis media in any population. 
The most serious limitation of the study is the conceptualization and measurement of the 
main outcome, AOM with TM perforation.  The potential for measurement errors from both 
overdiagnosis and underdiagnosis is so substantial that it raises serious doubts about the accuracy 
of the results.  Several other limitations of the analysis reduce its ability to detect the effect of the 
PCV on AOM with TM perforation.  Some of these are potential sources of bias toward the null 
hypothesis, such as the high percentage of infants who did not receive three doses of the PCV 
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and also the use of the Hib vaccine in the comparison group instead of a true placebo.  The 
relatively small sample size and short duration of data collection render the analysis inadequately 
powered to identify differences due to the PCV.  Having reliable data for only 6–24 weeks of 
age, a period when the incidence of AOM with TM perforation is among the lowest, made it 
even more difficult for the analysis to discern whether any statistically significant differences are 
caused by the PCV. 
Taken together these issues suggest that this analysis has poor internal validity, making it 
is difficult to determine whether the finding that the PCV does not cause a statistically significant 
difference in AOM with TM perforation is from the limitations of the analysis or is an accurate 
reflection of the truth for the study population.  As a result, no broader conclusions should be 
made from the results of this analysis and they should be considered to have little or no 
generalizability.  
Recommendations for Future Research 
This analysis set out to determine what effect the PCV has on the incidence and duration 
of episodes of AOM with TM perforation among infants in Bangladesh.  The analysis was 
unable to provide an acceptable answer to this question due to problems with internal validity.  
However, this question is still worth investigating as it is relevant to efforts to determine whether 
expansion of PCV coverage in India, China, and Indonesia might be beneficial and whether the 
PCV might be an effective strategy to reduce otitis media in countries where it causes high levels 
of morbidity and mortality. 
 On March 21, 2015, Bangladesh introduced a 10-valent PCV into its national 
immunization program.60  Although this makes it difficult, if not impossible, to conduct a 
placebo-controlled RCT on the effects of the PCV on otitis media in Bangladesh, it does create 
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new opportunities to examine this through some potentially valuable observational studies.  One 
example is a historical cohort study comparing otitis media before and after PCV introduction in 
Bangladesh.  Another example is a prospective cohort study comparing a group in Bangladesh to 
one in India that is as similar as possible except for not having universal immunization with the 
PCV.  These sorts of studies will not have the benefit of the randomized data that this analysis 
had.  Never the less, their results could be very helpful in determining the effect of PCV on otitis 
media in area with a high burden of disease.  Furthermore, investigation of this issue probably 
does not merit the significant expense that would likely be associated with conducting a new 
RCT to investigate this issue.  As a result, an observational study is probably the most 
appropriate type at this point. 
A historical cohort study comparing the effect of the newly-introduced 10-valent PCV on 
IPD is actually currently underway in the Sylhet district of Bangladesh.61  Coincidentally, the 
researchers conducting that study are from the same institutions that conducted the Mother’s Gift 
trial, the ICDDR,B and the Bloomberg School of Public Health at Johns Hopkins University.  
Including outcomes relevant to otitis media in a study like that one would be the most efficient 
way to answer the question investigated in this analysis.  Such an approach should attempt to 
avoid the limitations encountered in this analysis, which it could do by achieving a high level of 
adherence to the PCV schedule, using valid and accurate measurement techniques, limiting 
confounding variables as much as possible, and ensuring adequate sample size and appropriate 
timing and duration of data collection. 
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Table 1.  Maternal-Infant Vaccine Combinations 
 
 4 Possible Vaccine Combinations 
Maternal Vaccine: 
Infant Vaccine: 
PPV 
Hib 
PPV 
PCV 
Influenza 
Hib 
Influenza 
PCV 
 
 
Figure 1.  Group and Vaccine Assignments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pregnant mothers and their future 
infants randomized (n = 340 pairs) 
3rd Trimester maternal vaccine: 
Pneumococcal polysaccharide (n = 168) 
3rd Trimester maternal vaccine:  
Inactivated influenza (n = 172) 
Infant vaccine: 
Pneumococcal 
conjugate (n = 86) 
Infant vaccine: 
Pneumococcal 
conjugate (n = 85) 
Infant vaccine:  
H. influenzae 
type b (n = 82) 
Infant vaccine:  
H. influenzae 
type b (n = 87) 
Pneumococcal conjugate vaccine  
(PCV) group (n = 171) 
Haemophilus influenzae type B  
(Hib) vaccine group (n = 169) 
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Figure 2.  Flow Diagram 
 
823 pregnant women were assessed for eligibility 
 
272 declined to participate 
 
185 were not eligible based on the inclusion or exclusion 
criteria 
 77 were not planning to stay in the area after delivery. 
 68 had a previous history of systemic illness, pregnancy 
complication, preterm delivery, abortion, or birth with a 
congenital anomaly.  
 17 had a mismatch between their LMP and the clinical 
examination. 
 17 had a history of an allergic reaction to a vaccine 
 6 had a contraindication to a study vaccine. 
 
26 were eligible but did not return to the clinic 
  
 
340 pairs of pregnant women and their future infants were enrolled and randomized 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
165 infants were assigned to receive 3 doses of the PCV. 
 3 received 0 doses 
 29 received 1 dose 
 116 received 2 doses 
 15 received 3 doses 
 2 received 4 doses 
 
 
162 infants completed data collection through 24 weeks. 
 3 infants left the study prior to completion of data   
collection (12, 19, and 20 weeks).* 
 
 
165 infants had partial or complete data that was included  
in the analysis.
163 infants were assigned to receive 3 doses of the Hib vaccine. 
 4 received 0 doses 
 30 received 1 dose 
 118 received 2 doses 
 11 received 3 doses 
  
 
 
158 infants completed data collection through 24 weeks. 
 5 infants left the study prior to completion of data   
collection (7, 13, 14, 15, and 22 weeks).* 
 
 
163 infants had partial or complete data that was included  
in the analysis.
 
*The reasons that participants were lost to follow up are unknown.
6 infants left the study prior to the intervention: 
 2 pregnant mothers (and their future infants)       
were lost to follow up before delivery* 
 2 stillbirths 
 1 neonatal death (at 2 days of age) 
 2 infants lost to follow-up between delivery     
and 6 weeks of age* 
 7
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Hib Vaccine Group: (n = 169 infants) 
6 infants left the study prior to the intervention: 
 2 pregnant mothers (and their future infants) 
were lost to follow up before delivery* 
 1 stillbirth 
 2 neonatal deaths (at 3 and 19 days of age) 
 1 infant lost to follow-up between delivery 
and 6 weeks of age* 
 7
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     PCV Group: (n = 171 infants) 
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Table 2.  Participant Characteristics 
 
  
PCV Group 
(n = 165) 
Hib Vaccine Group 
(n = 163) 
Birth weight (kg) 3.14 3.02 
Birth weight < 2.5kg (%) 5.5 6.3 
Birth height (cm)  48.7 49.1 
Gestational age at birth (weeks) 39.4 39.6 
Gestational age <38 weeks (%) 15.2* 11.1* 
Mean Apgar score at 1 minute 8.35 8.03 
Mean Apgar score at 5 minutes 9.44 9.28 
Sex of infant is female (%) 44.8 42.3 
Infant born in a hospital or clinic (%) 94.5 89.6 
Infant born by Cesarean delivery (%) 53.9* 39.9* 
Maternal Age (years)  25.2 25.0 
Maternal height (cm) 153 153 
Maternal MUAC (mm) 266 260 
Maternal Gravidity 2.09 1.88 
Maternal Parity at enrollment 0.66 0.60 
Maternal education (years) 11.3 11.0 
Family owns house (%) 34.5 30.1 
Number of rooms in family home 3.76 3.52 
Someone who lives with the infant smokes (%) 46.1* 39.9* 
* Relative difference of >15% between the two groups 
 
 
Table 3.  Interview Timeliness by Group 
 
 Timeliness of interviews 
 Not late 1 week late 2 weeks late 3 weeks late ≥4 weeks late 
PCV Group 3015 (97.7%) 35 (1.1%) 16 (0.5%) 13 (0.4%) 6 (0.2%) 
Hib Vaccine Group 2933 (97.1%) 31 (1.0%) 28 (0.9%) 12 (0.4%) 16 (0.5%) 
 
 
Table 4.  Interviews and Positive Weekly Reports by Interview Type and Group 
 
 All interviews by  
group and type 
Positive weekly reports by 
group and type 
Interview Type PCV Group Hib Vaccine 
Group 
PCV Group Hib Vaccine 
Group 
Telephone 1539 (50%) 1365 (45%) 4 (31%)   9 (29%) 
Home Visit 1223 (40%) 1385 (46%) 5 (38%) 18 (58%)   
Clinic Visit 324 (10%) 270 (9%) 4 (31%)   4 (13%) 
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Figure 3.  Weekly Reports of AOM with TM Perforation by Week, Infant, Group and Antibiotics 
 
Vaccine 
 
Infants Weeks with positive reports of AOM with TM perforation 
6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
Hib 1                                   
 Vaccine 2                                   
 Group 3                                   
  4                                   
   5                                   
  6                                   
  7                                   
  8                                   
  9                                   
  10                                   
                     
PCV 1                                   
 Group 2                                   
  3       
 
  
 
                      
  4                                   
  5                                   
  6                                   
  7                                   
  8                                   
  9                                   
                     
 AOM with TM perforation was reported, but antibiotic use was not reported 
 AOM with TM perforation and antibiotic treatment for AOM were both reported   
 AOM with TM perforation and antibiotic treatment for a respiratory infection were both reported   
 
 
Table 5.  AOM with TM Perforation by Group 
 
  
PCV 
Group 
Hib Vaccine 
Group 
Risk Difference 
(95% C.I.) 
Infants included in the analysis 165 163  
Number of weekly interviews 3086 3020  
Number of weekly reports of AOM with TM perforation 13 31  
Number of infants with ≥ 1 episode of AOM with TM perforation 9 10  
Number of episodes of AOM with TM perforation 11 12  
Percentage of weeks with a positive report of AOM with TM 
perforation 
0.4%  
(13/3086) 
1.0%  
(31/3020) 
0.6%* 
(0.2% – 1.0%) 
Percentage of infants with at least one positive report of AOM 
with TM perforation 
5.4%  
(9/165) 
6.1%  
(10/163) 
0.7% 
(-4% – 6%) 
Percentage of weeks with a report of a new episode of AOM 
with TM perforation  
0.36% 
(11/3086) 
0.40% 
(12/3020) 
0.04% 
(-0.3% – 0.3%)  
*Bold value is statistically significant since the confidence interval does not include zero. 
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Table 6.  Episodes of AOM with TM perforation by Sex of Infants 
 
  Females Males 
Risk Difference 
(95% C.I.) 
Relative Risk 
(95% C.I.) 
Percentage of infants in the entire study with ≥ 
1 episode of AOM with TM perforation  
2.1%  
(3/165) 
8.0%  
(16/201) 
5.9% 
(1.5% – 10%) 
3.9 
(1.2 – 13) 
Percentage of infants in the PCV group with ≥ 1 
episode of AOM with TM perforation  
1.4%  
(1/74) 
8.8%  
(8/91) 
7.4% 
(1.1% – 13%) 
6.5 
(0.8 – 51) 
Percentage of infants in the Hib vaccine group 
with ≥ 1 episode of AOM with TM perforation  
2.9% 
(2/67) 
8.5% 
(8/94) 
5.6% 
(-1.3% – 13%)  
2.9 
(0.6 – 13) 
*Bold values are statistically significant 
 
 
Table 7.  Number of Weekly Reports per Episode by Group 
 
  
PCV 
Group 
Hib Vaccine 
Group 
 
 
/z/ statistic* 
 
 
p = * 
Mean number of weekly reports AOM with TM 
perforation per episode 
1.2   
(13/11) 
2.6  
(31/12) 
2.8 0.005 
Median number of weekly reports AOM with TM 
perforation per episode (with range) 
1 
(1-2) 
2 
(1-6) 
* From Wilcoxon rank-sum test 
 
 
 
Table 8.  Smoke Exposure by Group among Infants with AOM with TM Perforation 
 
  
PCV 
Group 
Hib Vaccine 
Group 
Risk Difference 
(95% C.I.) 
Percentage of infants with at least one report of AOM with TM 
perforation exposed to secondhand smoke at home 
44%  
(4/9) 
50%  
(5/10) 
6%  
(-39% – 50%) 
Percentage of episodes of AOM with TM perforation among 
infants exposed to secondhand smoke at home 
46%  
(6/13) 
55%  
(17/31) 
9% 
(-24% – 41%) 
 
 
 
Table 9.  Antibiotic Treatment by Group among Infants with AOM with TM Perforation 
 
  
PCV 
Group 
Hib Vaccine 
Group 
Risk Difference 
(95% C.I.) 
Percentage of reports of AOM with TM perforation with which antibiotic 
treatment was also reported 
85% 
(11/13) 
52%  
(16/31) 
33%* 
(7% – 59%) 
Percentage of episodes of AOM with TM perforation with which antibiotic 
treatment was reported during the first week of the episode 
82% 
(9/11) 
25%  
(3/12) 
57%* 
(23% – 90%) 
*Bold values are statistically significant since the confidence interval does not include zero. 
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Table 10.  Weekly Reports per Episode by Vaccine Group and Antibiotic Treatment during First Week 
 
Parameter Estimate t Value p = 
Vaccine 1.1 1.7 0.10 
Antibiotic treatment during the first week of the episode 0.61 1.0 0.33 
* Based on Generalized Linear Model 
 
 
 
Table 11. Common Causes of Ear Drainage in Infants 
 
Condition Ear Drainage Otoscopy Clinical History (Possible Symptoms) 
AOM with TM 
Perforation 
Purulent Perforated TM, which may be 
obscured by drainage. 
 
Recent or current fevers, runny nose, cough, 
and/or congestion.  Apparent otalgia. 
Otitis Externa Purulent or 
serous 
Intact TM. Inflammation along 
external auditory canal. 
 
Apparent otalgia. 
Foreign body Purulent, serous, 
and/or bloody 
Intact TM. Foreign body in 
external auditory canal.  
 
Something placed in the ear or has an older 
sibling.  May have fever and apparent otalgia 
Cerumen Yellow or brown-
tinged, waxy 
Intact TM. Cerumen in 
external auditory canal. 
 
Asymptomatic. No apparent otalgia. 
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APPENDIX A:  Otitis Media Terminology and Definitions 
 
Otitis media literally means inflammation of the middle ear.  It is a general term for a 
closely related group of disorders involving the middle ear.62,63  Many terms have been used to 
describe the different types of otitis media, resulting in confusion and misunderstanding among 
medical providers and researchers.63  Despite growing consensus regarding terminology and 
definitions, significant differences still persist.36,63-66  The analysis described in this master’s 
paper focuses on one type of otitis media, AOM with TM perforation.  The types of otitis media 
relevant to this paper are displayed in Figure A1 and described below.  
Figure A1. Relationships between common types of otitis media and tympanic membrane perforations29,63,64,67 
 
 
 
 
Chronic Suppurative Otitis Media 
(CSOM) (Active or Inactive) 
 
 
         
    
Acute Otitis Media (AOM)  
 
 
 
AOM with TM Perforation 
 
 
 
   Chronic TM Perforation* 
 
Otitis Media with Effusion (OME) 
 
 
 
TM Perforation without AOM* 
 
 
 
TM Perforation due to Trauma* 
 
 
*The three italicized conditions in the lower right quadrant of the figure are not types of otitis media, but they are 
included because they are closely related to the other conditions in the figure. 
Acute otitis media (AOM) is defined as the rapid onset of signs and symptoms of a 
middle ear infection, such as otalgia, fever, and a bulging TM.63,64  The diagnosis of AOM is 
based on clinical findings, and it does not differentiate between bacterial and viral causes.64  
Otitis media with effusion (OME) is defined as middle ear inflammation with accumulation of 
fluid in the middle ear without signs and symptoms of an acute infection.63,64  As depicted in 
Figure A1, OME can become AOM, if an acute infection develops.65  Conversely, AOM can 
become OME, if the signs and symptoms of acute infection resolve and fluid remains in the 
middle ear.64,65  
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AOM with TM perforation is the term for an acute infection of the middle ear that results 
in purulent otorrhea through a perforated TM, regardless of the cause of the perforation.63,66  
(Some refer to this simply as AOM with perforation.63)  TM perforation occurs most commonly 
as a complication of AOM.63,68  When TM perforation occurs due to OME or trauma, it can heal 
spontaneously, persist as a chronic TM perforation, or become infected leading to AOM with 
TM perforation.36,63,68   
 When complete resolution of AOM with TM perforation does not occur, it progresses to 
one of the two chronic conditions in Figure A1.63  If the middle ear infection resolves, but the 
TM does not heal, then it becomes a chronic TM perforation.63  When all the features of AOM 
with TM perforation continue for greater than 6 weeks, then it is considered chronic suppurative 
otitis media (CSOM), which is persistent  middle ear inflammation, TM perforation, and purulent 
otorrhea.36,63  CSOM is subdivided into active and inactive types depending on whether otorrhea 
is currently present or not.36,63  CSOM is notable because it is responsible for most of the 
morbidity and mortality due to otitis media worldwide.29,36  AOM with TM perforation, which is 
the primary focus of this analysis, is significant in large part because it is the main precursor 
condition to CSOM. 
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APPENDIX B:  Burden of Suffering due to Otitis Media 
Otitis media is important on both the individual health and public health levels.  Although 
the various types of otitis media can often resolve spontaneously or with a course of antibiotics, 
they can sometimes lead to serious complications.  This appendix describes the significant 
complications of otitis media, reviews a select group of studies on the complications of otitis 
media, and summarizes the global and regional estimates of morbidity and mortality due to otitis 
media. 
Complications of Otitis Media 
Most often, complications from otitis media occur when bacterial infections in the middle 
ear spread to adjacent ear and central nervous system structures resulting in damage to and 
dysfunction of those structures.69  Complications are often divided into two groups, intratemporal 
and intracranial.63,70-74  Intratemporal complications include conductive and sensorineural 
hearing impairment (HI), cholesteatoma, facial nerve paralysis, labyrinthitis, mastoid abscess, 
mastoiditis, ossicular discontinuity, and vestibular dysfunction.27,31,63,75-80  Intracranial 
complications include brain abscess, cerebral venous sinus thrombosis, epidural abscess, 
meningitis, otitic hydrocephalus, perisinus abscess, and subdural empyema.31,63,74-83  The one 
routinely occurring complication that is neither intratemporal nor intracranial is 
sternocleidomastoid abscess (Bezold’s abscess).70,76,78,80,82  Although otitis media often resolves 
without causing serious complications, individuals with the above sequelae can experience 
significant short-term disability, long-term disability, and even death.74-76,78,80-82 
Evidence for the common complications of otitis media listed above comes mostly from 
retrospective chart reviews of patients who were seen at otolaryngology clinics or admitted to 
otolaryngology services at tertiary care hospitals.  Most of the publications are single case 
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reports, case series, cross-sectional studies, or case-control studies.  A systematic search of 
PubMed, Ovid MEDLINE, and Cochrane Databases by Jung et al. found 127 relevant studies 
published just between 2007 and 2011.84  Thorough reviewing of that many articles is beyond the 
scope of this paper, but I did perform a focused PubMed search was performed to investigate the 
complications of otitis media.  A search for “otitis media,” “complications,” and “intracranial,” 
limited to articles published after 1990, in English, and with human subjects, yielded 288.  
Review of the titles and abstracts of those 288 articles identified 36 relevant articles.  I chose to 
further narrow the results by only including studies with ≥20 subjects with intracranial 
complications to capture a greater number of subjects with serious complications.   This yielded 
13 studies for in-depth review.74-78,81-83,85-89  Review of those articles uncovered 2 additional 
articles that were appropriate to include in this in-depth review.31,80 
The studies included patient data from as early as 1978.  Based on the World Bank 
classification method, fourteen of the studies are from middle income countries, and one is from 
a high income country.31,74-83,85-90  Seven of the studies include patients with otitis media with 
and without complications.31,75,76,78,81,85,86  Eight of them are case series of only patients with 
complications.74,77,80,82,83,87-89  Nine of the studies only include patients with CSOM.31,76-78,80,82,87-
89  My review of these studies yielded a few interesting observations. 
Several studies reported whether patients’ complications were due to AOM or CSOM.  
Among 422 subjects in Egypt with intracranial and/or extracranial complications, 98% had 
CSOM and 2% had AOM.85  Among 285 subjects in China with intracranial and/or extracranial 
complications, 96% had CSOM and 4% had AOM.86  Among 102 subjects in Thailand with 
intracranial and/or extracranial complications, 90% had CSOM and 10% had AOM.75  About 
half of those subjects were also included in a study of 87 patients in Thailand with intracranial 
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complications, of whom 94% had CSOM and 6% had AOM.81  Among 33 patients in Brazil with 
intracranial complications, 82% had CSOM and 18% had AOM.74  Results from these studies 
support the expert opinion that most of the morbidity and mortality from otitis media is due to 
CSOM.69,91  Conversely, the one study from a high income country, Israel, reported that among 
the 28 patients with intracranial complications, 29% had ASOM and 71% had AOM.83  This is 
likely because CSOM is less frequent in Israel, which like most other high-income countries, is 
classified in the lowest CSOM prevalence category (<1%) by the WHO.36 
The fifteen studies described a total of 986 subjects with intracranial complications due to 
otitis media, most of whom also had intratemporal complications.  There were 86 deaths (8.7%) 
among these subjects.  By contrast, there were no deaths noted among the 1,522 subjects with 
only intratemporal complications of otitis media in these studies.  The mortality rates varied 
greatly between the studies.  The highest mortality for intracranial complications was reported in 
studies from New Guinea (31%, 10/33), Turkey (26%, 15/57), and Thailand (18%, 16/87).76,81,82  
The lowest mortality was reported in a different study from Turkey (0%, 0/50) and studies from 
Israel (0%, 0/28) and Egypt (2.6%, 6/228).77,83,85  Despite the obvious heterogeneity of these 
studies, they do provide convincing evidence that the overwhelming, if not all, of the deaths due 
to otitis media occur due its intracranial complications.  Brain abscess, meningitis, cerebral 
venous sinus thrombosis, and subdural empyema were the most commonly mentioned 
complications leading to the deaths in these studies.74-76,78,80-82   
There is significant variability in many aspects of the studies I reviewed. There are 
multiple explanations of this variability.  Study populations were different in the severity of the 
disease at baseline.  Also, the incidence, prevalence, severity and course of otitis media vary 
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widely between and within countries, depending on numerous factors such as socioeconomic 
status, environmental conditions, and access to medical care and treatment.36  
Estimates of Morbidity and Mortality due to Otitis Media 
Several estimates of the worldwide morbidity and mortality due to otitis media have been 
made by extrapolating from available data using statistical modeling.  Since 1990, the World 
Health Organization (WHO) has been involved in efforts to assess the global burden of disease, 
publishing estimates of global morbidity and mortality due to about 100 different causes, one of 
which is otitis media.92,93  The WHO global burden of disease estimates are available for 1990, 
2000-2002, 2004, 2008 and 2011.92  The Institute for Health Metrics and Evaluation (IHME), a 
research center at the University of Washington, built on the work done by the WHO to produce 
estimates for 1990 and 2010, which were published in 2012.32,94  The IHME collaborated with 
six other institutions around the world, including the WHO, and provided estimates for 291 
different causes of morbidity and mortality.32  Monasta et al. provide an estimate for global 
mortality due specifically to otitis media in 2005.29  Table B1 displays all of these estimates, 
except for the WHO estimates for 2001, 2002, and 2008, which were omitted for the sake of 
brevity since they were similar to other estimates. 
Table B1. Selected estimates for morbidity and mortality due to otitis media 
Year of Estimate Author (Publication Date) 
Mortality 
(Deaths per year) 
Morbidity 
(Millions of DALYs per year) 
1990 WHO (1996)93 28,000 2.2 
1990 IHME (2012)1,2 5,200 4.2 
2000 WHO (2001)95 6,000 1.4 
2000 revised WHO (2013)96,97 3,500 4.8 
2004 WHO (2008)98 5,000 1.5 
2005 Monasta et al. (2012)29 21,000 Not calculated 
2010 IHME (2012)1,2 3,500 4.7 
2011 WHO (2013)96,97 3,100 5.1 
2013 IHME (2015)4 2,400 Not calculated 
Range of Estimates for Years 1990 – 2011 2,400 to 28,000  1.4 to 5.1    
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As seen at the bottom of Table B1, there is a wide range for the estimates of morbidity 
and mortality due to otitis media.  Mathers et al. explain that the WHO estimates published prior 
to 2013 used different methods and data sources.99,100  As a result, the changes in the WHO 
estimates over time could be due to the use of different methods and data sources, actual 
differences in the level of disease, or a combination of both.  Time series comparisons are only 
valid for the IHME 1990 and 2010 estimates and for the WHO 2000 revised and 2011 
estimates.32,99,100  Both sets of comparisons show a small decline in deaths and a small increase 
in DALYs due to otitis media.   
Disparities in the Burden of Suffering due to Otitis Media 
Age-Related Disparities 
 Monasta et al. calculated the one estimate of mortality in due to otitis media in Figure 1 
that is not from a larger global burden of disease project.  Their study focused specifically on 
otitis media and calculated global incidence rates for AOM and CSOM, hearing impairment (HI) 
prevalence and deaths due to otitis media.  Their estimates were broken down by age and by the 
21 WHO region areas used in the 2010 Global Burden of Disease study.29,32  Table B2 illustrates 
some basis epidemiologic trends with otitis media.  AOM and CSOM incidence peak in early 
childhood, however greater prevalence of CSOM will be seen into adolescence and early 
adulthood, since the average duration is 1-3 weeks for ASOM and 10 years for CSOM.29,101 
Prevalence of hearing impairment due to otitis media gradually increases throughout the lifespan.   
Deaths due to otitis media are greatest among infants, young children, and the elderly.   
Geographic Disparities 
The six WHO region areas whose estimates were above the global average in all four 
categories were included in Table B3.  The other fifteen WHO regions were below the global 
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average in all four categories.  Monasta et al. also estimated that the South Asia WHO region 
area (Afghanistan, Bangladesh, Bhutan, India, Nepal, and Pakistan), which had 23% of the 
world’s population, accounted for 48% of the deaths due to otitis media.29,32  For hearing 
impairment (HI) due to otitis media, they estimated that South Asia accounted for 75% of 
moderate HI, 85% of severe HI, and 93% of profound HI due to otitis media.29,33   
Table B2. Global AOM and CSOM incidence, HI prevalence, and deaths for 2005 by age 
Age 
(years) 
AOM 
% incidence 
CSOM 
% incidence 
HI>25dB best ear 
prevalence per 10,000 
Deaths per 
10,000,000 
<1 45 15 9.3 85 
1–4  61 10 23 91 
5–9  22 8.3 26 39 
10–14  19 3.9 27 33 
15–19  3.5 3.4 27 19 
20–24  3.1 4.8 30 14 
25–34  1.6 3.3 31 14 
35–44  1.5 3.2 33 19 
45–54  1.8 4.1 35 15 
55–64  1.9 3.7 40 23 
65–74  2.1 2.5 45 49 
75–84  2.3 2.6 43 156 
85+  2.3 2.7 38 179 
Global mean 
for all ages      11 4.8 31 
33 
Adapted from Monasta et al.29 
 
Table B3. AOM and CSOM Incidence, HI Prevalence, and Deaths for 2005 by Selected WHO Region Areas 
WHO 
Region 
AOM 
% incidence 
CSOM 
% incidence 
HI>25dB best ear 
prevalence per 10,000 
Deaths per 
10,000,000 
Asia South  15 6.6 97 69 
Oceania  29 9.4 51 101 
SSA Central  43 7.6 30 96 
SSA East  23 6.1 32 73 
SSA South  15 4.8 9.4 34 
SSA West  43 7.2 34 92 
Global mean 
for all regions       11 4.8 31 
 
33 
SSA = Sub-Saharan Africa.  Adapted from Monasta et al.29 
48 
 
Economic-Related Disparities  
Some of the WHO Global Burden of Disease estimates group together countries by 
income level and by region, which also reveals disparities in the burden of suffering due to otitis 
media.  These estimates use the World Bank classification system to divide countries into low-
income, middle-income, and high-income groups, based on each country’s average per capita 
gross national income.90,102  Low-income and middle-income countries account for about 80% of 
the world’s population.103  However, in the WHO estimates for 2000, 2002, 2004, and 2011, 
low-income and middle-income countries accounted for 94-96% of deaths and 90-93% of 
DALYs due to otitis media.96-98,104  The WHO figures for 2000 (revised) and 2011 provide 
estimates for each of the seven World Bank regions.90,96,97  Table B4 includes estimates for the 
three regions with the highest numbers of deaths and DALYs due to otitis media.  It shows that 
South Asia and Sub-Saharan Africa regions account for disproportionally greater shares of the 
burden of disease due to otitis media relative to their populations.    
Table B4. WHO Estimates of Morbidity and Mortality from Otitis Media by Selected World Bank Regions 
World Bank Region90 
Percentage of world 
population in 
2012105 
Deaths due to Otitis Media 
(Percentage of world total)96 
DALYs due to Otitis Media 
(Percentage of world total)97 
2000 2011 2000 2011 
East Asia and Pacific 28% 10% 9% 29% 26% 
South Asia 23% 35% 26% 28% 28% 
Sub-Saharan Africa 13% 31% 44% 16% 21% 
 
 
Methods for Estimating Morbidity and Mortality due to Otitis Media 
Murray and Lopez were the senior authors of the IHME estimates, and they were 
involved in many of the WHO estimates.93,99,100  They criticize the WHO estimates for relying on 
methods that are too subjective.32  They argue that the IHME estimates use a more systematic 
approach.32  Alternatively, the WHO has not officially endorsed the IHME results due to 
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concerns about some substantial differences (not necessarily involving otitis media) between the 
WHO and IHME estimates.99 
The IHME and WHO publications do not discuss the specific source data for otitis media 
in their methodology,1,2,99,100 but Monasta et al. describe it in detail.29  They identify several 
significant gaps in the source data, which they deal with through extrapolation and by making 
assumptions about the nature of AOM and CSOM.29  Worldwide estimates of the burden of 
disease due to otitis media help put the significance of otitis media in perspective.  However, 
their accuracy is uncertain due to incomplete source data and statistical methodologies dependent 
on assumptions and extrapolation.  
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APPENDIX C   
Manuscript Prepared for Submission for Publication by Dane Warner and Mark Steinhoff 
 
 
Clinical Effectiveness of a Pneumococcal Conjugate Vaccine 
in Acute Suppurative Otitis Media: A Randomized Controlled Trial in Bangladeshi Infants 
 
Otitis media is a significant cause of morbidity and mortality worldwide.  According to 
the World Health Organization (WHO), otitis media was responsible for approximately 5,000 
deaths98 and the loss of 1.5 million disability-adjusted life years (DALYs) in 2004.98  This 
morbidity and mortality are primarily due to the suppurative forms of otitis media, which occur 
when a middle ear infection is accompanied by tympanic membrane perforation and purulent 
otorrhea.91  Initially, such an infection is termed acute suppurative otitis media (ASOM).106  If 
the infection and otorrhea persist for more than 2 weeks, it is then considered chronic 
suppurative otitis media (CSOM), according to the WHO definition.36  CSOM can last for many 
years, and it is responsible for the vast majority of otitis media complications.91  These include 
hearing impairments and contiguous and systemic infections, such as mastoiditis, brain abscess, 
subdural empyema, meningitis, and sepsis.36,67,91   
Approximately 95% of the morbidity and mortality from otitis media occurs in children 
in developing countries.93  Africa, South-East Asia, and the Western Pacific account for an 
estimated 93% of the global disease burden for CSOM.36  The WHO considers a CSOM 
prevalence of greater than 4% to be a massive public health problem.36  The estimated 
prevalence rates for these three regions range from 4.2–10%.36  Some ethnic groups have been 
found to have very high prevalence rates, including Australian Aborigines (15-43%),36,67,107 
Inuits (7-46%),67,108 and some Native American groups (Apache and Navajo, 4-8%).50,67  Our 
study analyzes data collected in Bangladesh, where estimated CSOM prevalence rates range 
from 7% to 12%.47,48,109   
A study of otitis media incidence in Bangladesh, which followed 252 children from birth 
to 24 months, reported that 115 children (46%) had at least one episode of otitis media.47  A total 
of 375 episodes of otitis media were diagnosed by physicians using otoscopy.  14% of the 
episodes were otitis media without perforation, and 86% were accompanied by otorrhea and 
classified as ASOM.  5% of the episodes were classified as CSOM, which in this study required 
a duration of greater than 6 weeks.47  
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 Efforts to decrease CSOM have included improving environmental conditions, expanding 
access to medical services, and enhancing health care quality.36,50  There is some evidence that 
these approaches can be effective, but they require significant resources and many years before 
substantial effects are observed.36,50  As a result, there is interest in other strategies for decreasing 
CSOM and its complications.50  Among the possible strategies, immunization has the greatest 
potential for achieving positive results in areas where there is a high prevalence of CSOM.110 
The most common bacteria isolated from otitis media is streptococcus pneumoniae,28,35 
making it an appropriate target for prevention through immunization.  Five randomized 
controlled trials have investigated the effect of infant immunization with pneumococcal 
conjugate vaccines (PCVs) on otitis media.28,34,35,111,112  They have demonstrated modest 
reductions in incidence of otitis media, ranging between –1% and 33%, in high resource 
countries with low rates of CSOM, but a substantial effect on culture proven otitis media caused 
by streptococcus pneumoniae.28,34,35,111,112  None of these studies examined the effect PCVs 
specifically on ASOM episodes.28,34,35,111,112  The only study of PCVs and ASOM in a high 
CSOM prevalence population was a before/after study that compared an Australian Aboriginal 
infants born before universal immunization with PCVs to those born afterwards.113  The study 
found no differences in the rates of otitis media without perforation, ASOM or CSOM.113  Our 
study is the only RCT we are aware of that examines the effectiveness of a PCV against ASOM 
in a population with high ASOM and CSOM prevalence. 
Methods 
Study Design 
This study is a secondary analysis of data from the Mother’s Gift trial, which investigated 
the safety and immunogenicity of sequential maternal and infant immunization with 
pneumococcal vaccines.  Mother’s Gift was a prospective, blinded, individually randomized, and 
comparison-controlled trial (see ClinicalTrials.gov number NCT00142389).  The design and 
results of the Mother’s Gift trial have been previously described.16,20  
This secondary analysis examines the effect of infant PCV on acute suppurative otitis 
media in infants from 10 to 24 weeks of age.  Maternal participants were recruited from three 
urban, antenatal clinics in Dhaka, Bangladesh.  All women in their third trimester of pregnancy, 
who attended one of these three clinics between August 2004 and May 2005, were invited to 
participate.  All data were collected between August 2004 and November 2005.  Pregnant 
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women were excluded from the study if they had a chronic disease, contraindication to a study 
vaccine, previous or current high-risk pregnancy, previous medical or spontaneous abortion, 
previous receipt of a study vaccine in the last 3 years, or plans to not live in Dhaka after delivery.   
Upon enrollment in the Mother’s Gift trial, the pregnant women and their infants were 
randomly assigned to one of four groups.  Randomization was performed using a computer-
generated sequence that was developed centrally before study enrollment began.  Randomization 
was stratified according to clinic and was blocked into four groups.  Sequentially-numbered, 
opaque envelopes with the study group assignments were provided to the three obstetrical 
clinics.  Participants and study staff who collected data were unaware of the study group 
assignments.   
Half of the infants were in the PCV group and received the 7-valent pneumococcal 
conjugate vaccine (PCV-7) (Prevnar, Wyeth).  The other half of the infants were in the Hib 
group and received the Haemophilus influenzae type b (Hib) conjugate vaccine (Hiberix®, 
GlaxoSmithKline).  Pregnant women received either the 23-valent pneumococcal polysaccharide 
vaccine (PPV) (Pneumovax®, Merck) or the inactivated influenza vaccine (Fluarix®, 
GlaxoSmithKline).  Randomization was designed so that for both the PCV group and the Hib 
group, one half of the infants had mothers who received the PPV, and the other half had mothers 
who received the influenza vaccine.16  See Table C1, Patient Characteristics. 
Pregnant women received one dose of their assigned vaccine (PPV or influenza vaccine) 
during the third trimester of pregnancy.  Infants received three doses of their assigned vaccine 
(PCV or Hib vaccine) at 6, 10, and 14 weeks of age.  All vaccine doses were administered 
through intramuscular injection.  All study vaccines were purchased from the manufacturers.  
Clinic staff administering the vaccines were aware of the group assignments, but they were not 
involved with the measurement of any study outcomes.  All other clinic staff and all family 
members were blinded to group assignments.  
The sample size was determined for the purpose of the original Mother’s Gift trial.16  It 
was powered to detect a difference in the mean pneumococcal antibody titers of the infants.  336 
subjects were deemed necessary for the Mother’s Gift trial.  This was based on standard 
formulae, reported local antibody variance data, a 2-sided α = 0.05, a β = 0.20, and an assumed 
25% attrition rate.16  
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 The Mother’s Gift trial protocol was reviewed and approved by the institutional review 
boards at the International Centre for Diarrheal Disease Research, Bangladesh, and the 
Bloomberg School of Public Health at Johns Hopkins University, Baltimore.  Use of study 
vaccines was approved by the Directorate of Drug Administration of the Government of the 
People's Republic of Bangladesh.  All authors vouch for the completeness of the data and the 
analyses presented.   
Measurement 
Mothers of the infants were interviewed every week from birth until 24 weeks of age, 
according to the original study protocol.  Interviews were conducted by field workers, who were 
trained and overseen by study supervisors.  Mothers were asked about illness symptoms and 
infant feeding.  Relevant to the current analysis, each mother was asked if her infant had an ear 
problem during the last week.  If the answer was yes, she was asked if there had been drainage 
from one ear, both ears, or neither ear during the last week.  All reports of ear drainage were 
considered to represent otorrhea due to ASOM.  Mothers were also asked what type of 
treatments they had used for the ear problem.  If an infant’s mother was not present, a 
knowledgeable caregiver was interviewed if one was available. 
 Monitoring for adverse events was conducted through the weekly interviews.  An 
independent data and safety monitoring board and the institutional review boards in both 
Bangladesh and Baltimore reviewed all severe adverse events. 
Results 
Analysis 
PCV does not generate protective antibody titers until after an infant receives its second 
PCV injection.57  As a result, this analysis examined data collected from 10 weeks, when the 
second PCV shot was administered, to 24 weeks or age, when data collection stopped.  There 
were no reports of otorrhea before 10 weeks of age, so no ASOM episodes were excluded from 
the analysis. 
Data regarding ASOM were estimated from weekly reports of otorrhea as follows. 
Reports of otorrhea separated by one or more weeks without otorrhea were considered to 
represent distinct episodes of ASOM.  Since each weekly report of otorrhea reflected ASOM 
during part of the previous week, but not necessarily for the whole previous week, the first and 
last weekly reports of any ASOM episode were assigned an estimated duration of 3.5 days.  Any 
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weekly reports between the first and last weeks were assigned a duration of 7 days, based on the 
assumption that any consecutive weekly reports represented one continuous episode.   
Participants 
A total of 340 pregnant women met the inclusion criteria and agreed to have their infants 
participate in the study.  All 340 infants were randomized while in utero (PCV group n = 171, 
Hib group n = 169).  Data were available between 10 and 24 weeks for 327 infants (PCV group n 
= 165, Hib group n = 162).  All results reflect analysis of data from these 327 infants.  See Figure 
C1, Study Diagram. 
The infants in the two groups were similar in all demographic and biometric 
characteristics, with the exception of Cesarean delivery, which occurred with 54% of births in 
the PCV group and 40% of births in the Hib group (p = 0.01).  See Table C1, Participant 
Characteristics. 
Data collection was complete for 99% of weeks in the PCV group and 98% of weeks in 
the Hib group.  5 infants (3%) in each group were lost to follow up between 10 and 24 weeks.  
Interviews were conducted either over the phone (48%), during a home visit (43%), or while at a 
clinic visit (9%). 
When one or more interviews were missed, data for two or more weeks were collected at 
the next interview.  The percentage of interviews conducted one or more weeks late was similar 
between the two groups.  Average lateness per interview was also similar.  
Effectiveness 
There were 5.5% and 6.2% of infants in each group who had ≥ 1 ASOM episode in the 
PCV and Hib groups, respectively (p = 0.79).  ASOM episodes per 100 child-months were 1.95 
for the PCV group and 2.18 for the Hib group (p = 0.80).  Mean ASOM episode duration was 4.1 
days per episode for the PCV group compared to 12.2 days per episode for the Hib group (p = 
0.0048).  The difference in mean episode durations was 8.1 days (95% CI, 1.5–14.7), with a 
reduction in episode duration of 66%.  Overall, the infants in the PCV group experienced 70% 
fewer days of ASOM per 100 child months compared to infants in the Hib group (6.1 vs. 26.7,  p 
< 0.0001).  See Table C2.  
The incidence of ASOM in the whole study population (n=327) using data collected from 
birth to 24 weeks was 0.074 episodes per 6 child months.  Among the 19 infants who had at least 
one ASOM episode, 16 were males and 3 were females (Fischer Exact two-tailed p = 0.0087).  
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Among the 9 infants in the PCV group with ASOM, 1 (11%) was female (Fischer Exact two-
tailed p = 0.039).  Among the 10 infants in the Hib group with ASOM, 2 (20%) were female 
(Fischer Exact two-tailed p = 0.19).  
Two infants in the Hib group accounted for 4 of the 12 ASOM episodes, 15 of the 31 
weekly reports of ASOM, and 80.5 of the 147 days of ASOM.  (See Figure C2, rows 8 and 10.)  
None of these 4 episodes were treated with antibiotics during the first week of the episode.  3 of 
the episodes were treated with antibiotics on the second week.  The other was treated on the 
fourth week of the episode.  Both of the infants were males born at 40 weeks gestation.  One of 
the infants weighed 3.4kg (62nd percentile) at birth and 6.1kg (1st percentile) at 24 weeks.114  No 
weights were recorded for the other infant. 
Discussion 
This analysis suggests that the administration of PCV at 6, 10, and 14 weeks may 
substantially decrease the duration of ASOM episodes in young infants.  The magnitude of the 
PCV’s effect is evidenced by the large (70%), statistically significant reduction in prevalence, 
despite a relatively small number of episodes (11 in the PCV group and 12 in the Hib group).  
Since PCV appears to reduce the duration of ASOM episodes, there is a possibility that PCV 
may also decrease the progression of ASOM to CSOM, which could lead to a significant 
reduction in the morbidity and mortality due to otitis media, which occurs predominantly due to 
CSOM.  Kaplan et al. demonstrated this relationship in a study in Alaska in the 1960’s.108  They 
found that children with a history of otitis media as infants were twice as likely to have hearing 
loss at 10 years of age.108  They also showed that having ASOM episodes of longer duration may 
predispose children to developing CSOM and its complications.108 
 The strengths of this analysis include its blinded, randomized design and its prospective 
data collection with frequent surveillance through weekly interviews.  Randomization was 
effective and achieved groups with similar baseline characteristics.  The study had a high level of 
data completeness and a low percentage of infants lost to follow up in both groups. 
 Although the study was not placebo-controlled, it was essentially comparison-controlled 
using the Hib vaccine.  The Hib vaccine is not effective against the nontypeable strains of 
Haemophilus influenzae which cause 12% to 23% of otitis media episodes.14  Hib is a causative 
agent in otitis media on rare occasions (0.4% of cases),28 so the Hib vaccine is unlikely to have 
had a significant effect on ASOM in infants who received it.  Furthermore, if the Hib vaccine 
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provided protection against ASOM, it would lead to an underestimation of the effect of the PCV 
on ASOM. 
The study was limited by the lack of bacteriologic and clinical exam data.  However, 
since diagnosis of ASOM was based on parental report of ear drainage, only severe cases were 
detected.  Among these severe and presumably more clinically relevant cases, the efficacy of the 
PCV for reducing ASOM episode duration was clear.   
Noticing ear drainage is a fairly simple task, but using parental report of otorrhea for 
detection of ASOM may have resulted in both under-diagnosis, when parents did not notice 
drainage, and over-diagnosis, when parents noted cerumenous discharge that was mistaken for 
otorrhea.  Even though parental report may have led to inaccuracy in detection of ASOM, it 
should not have led to any differential bias. 
4.9% of data was from late interviews, which involved recall of information from greater 
than 7 days earlier. Since the average lateness of the interviews was similar in both groups, this 
would not cause a differential bias.  Because none of the reports of ASOM were from late 
interviews, underestimation of ASOM episodes would be possible, but not overestimation. 
Many previous studies have confirmed the safety of the vaccines given to both groups of 
infants.34,44,57-59  As a result, there is no reason to expect any differences in hospitalizations or 
adverse events between the two groups.  
The sex differences in the incidence of ASOM in our analysis are striking.  There are 
multiple plausible explanations for this difference.  One likely significant contributor is a 
parental bias of increased attention to the symptoms of male infants compared to female infants.  
Hossain et al. demonstrated such a bias in the nearby rural area of Matlab, Bangladesh.51  
However, the difference found in our analysis could reflect a true difference in disease.  Roy et 
al. found that 63% (236/375) of episodes of otitis media in the first two years of life occurred in 
males.47  Jensen et al. found that in Greenland boys and girls had equal risk of developing 
CSOM, but that girls had higher much higher rates of spontaneous healing, resulting in boys 
having increased rates of CSOM persistence.115    
For the first 24 weeks of life, this analysis found an incidence of 0.074 episodes of 
ASOM per 6 child months.  Roy et al. identified approximately 0.25 episodes of acute otitis 
media per 6 child months during the first 6 months of life.  This discrepancy is most likely due to 
our study population being urban and the Roy et al. study population being rural, as other studies 
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have documented higher percentages of otitis media in rural settings.48-50  The incidence from 
Roy et al. is based on 61 episodes, an uncertain percentage of which are acute otitis media 
without otorrhea (Overall the study identified 375 episodes between birth and 24 months, 53 
(14%) of which were otitis media without otorrhea.  Furthermore, their measurement of otitis 
media was likely more sensitive since they conducted interviews every 4 days instead of every 7. 
The findings of this analysis are unique and would need to be replicated before a 
definitive conclusion can be made.  In this analysis, PCV caused a large and statistically 
significant reduction in ASOM and CSOM.  Worldwide there is substantial morbidity and 
mortality caused by ASOM and CSOM.  This effect certainly merits further investigation, since 
confirmation of it would suggest that PCV may have significant beneficial effects in addition to 
its already recognized ability to decrease invasive pneumococcal disease.  To follow up on this 
analysis, plans are being made to assess the hearing of the original participants of this study to 
measure the effects of PCV on long-term ASOM and CSOM-related morbidity. 
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Figure C1. Study Diagram 
823 pregnant women screened 
 
 
483 were not enrolled 
 
 
340 Infants enrolled and randomized (before birth) 
 
 
 
Pneumococcal Conjugate Vaccine (PCV) Group  Haemophilus influenzae type B (Hib) Vaccine Group  
171 infants assigned to receive PCV   169 infants assigned to receive Hib vaccine  
 
   
 
6 infants lost to follow up before intervention   7 infants lost to follow up before intervention 
 
 
 
165 infants with data available for analysis    162 infants with data available for analysis 
Data collected for 99% of weeks    Data collected for 98% of weeks 
81% had 2 or more doses of PCV    80% received 2 or more doses of Hib vaccine 
5 infants lost to follow up between 10 and 24 weeks  5 infants lost to follow up between 10 and 24 weeks 
 
Table C1:  Patient Characteristics Experimental Group 
(PCV) n = 165 
Comparison Group 
(Hib) n = 162 
P value 
Maternal Age (yr) 25.18 24.93 0.60 
Parity 1.12 1.14 0.88 
Maternal inactivated influenza vaccine 
(%) 49.70 50.62 0.87 
Maternal Pneumococcal polysaccharide 
vaccine (%) 50.30 49.38 0.87 
Maternal height (cm) 152.80 152.70 0.94 
Maternal education (yr) 11.27 10.96 0.43 
Family owns house (%) 34.55 30.25 0.41 
Rooms in house (Number) 3.76 3.53 0.27 
Smoker in family (%) 46.06 39.51 0.23 
Gestational age at birth (wk) 39.43 39.58 0.44 
Infants born in a hospital or clinic (%) 94.55 89.51 0.09 
Infants with Cesarean delivery (%) 53.94 40.12 0.01* 
Birth weight (kg) 3.22 3.19 0.80 
Weight at 6 wks (before first vaccination) 4.36 4.25 0.19 
Mean Apgar score at 1 minute 8.35 8.32 0.98 
and 5 minutes 9.47 9.36 0.92 
Sex of infant female (%) 45.45 41.36 0.45 
Duration of exclusive breast-feeding (wk) 15.63 15.50 0.90 
*Means were compared using the Student’s t-test. Proportions were compared using Fisher’s exact test. 
‡ The rate of cesarean delivery was typical for the population of patients at the study centers. 
§ The Apgar scores are 0 to 10.  Scores above 7 indicate that the baby’s condition is good to excellent. 
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Table C2.  Measurements of ASOM and CSOM for the PCV and Hib Vaccine Groups 
 
  
PCV 
Group 
Hib Vaccine 
Group  P Value 
Relative 
Rate or 
Difference 
in Means 
(95% CI) 
Infants 165 162   
Infant months observed 564.30 551.41   
Infants with one or more episodes of ASOM 9 (5.5%) 10 (6.2%) 0.7874  
Episodes of ASOM 11 12      
Episodes of ASOM per 100 child months 1.95 2.18 0.7956  
Episodes of CSOM (duration > 2 weeks) 0 4   
Episodes of CSOM per 100 child months 0 0.73 0.0597  
Total days of ASOM per group  45.5 147      
Mean duration of ASOM episode* 4.14 12.25 0.0048* 
8.11 (1.53, 
14.70) † 
Days of ASOM per 100 child months 8.06 26.66 <0.0001  
Days of ASOM per infant with ASOM 5.06 14.7      
Age in days at time of first report of ASOM 114.33 125.30 0.47  
Weekly reports of ASOM 13 31       
0.41 (0.21, 
0.78) § 
 
*Wilcoxon test used due to small sample size 
† Difference in Means 
§ Relative Rate 
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Figure C2:   Weeks with reported ASOM, 10-24 weeks of age, by infant vaccine 
 
  
Age in Weeks 
           Vaccine Case 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 
Hib 1                               
  2                               
  3                               
  4                               
  5                               
  6                               
  7                               
  8                               
  9                               
  10                               
PCV7 1                               
  2                               
  3                               
  4                               
  5                               
  6                               
  7                               
  8                               
  9                               
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